Core Viewpoint - The company, Dongfang Ocean, announced that its wholly-owned subsidiary, Aiveke Biotechnology Co., Ltd., has received a medical device registration certificate from the Shandong Provincial Drug Administration for its high-sensitivity cardiac troponin I (hs-cTnI) assay kit, which is approved for market launch [2] Group 1 - The hs-cTnI assay kit is designed for the quantitative detection of cardiac troponin I levels in human serum, plasma, and whole blood [2] - The product has been certified but has not yet been put into production, and its actual sales will depend on market expansion efforts and actual market demand [2] - The impact of Aiveke Biotechnology Co., Ltd. on the company's performance this year has been minimal, and the production and subsequent effects remain uncertain [2]

证券代码：002086 证券简称：东方海洋 公告编号：2025-070 山东东方海洋科技股份有限公司 关于全资子公司取得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或者重大遗漏。 特别提示： 1. 艾维可生物科技有限公司今年对公司的业绩影响较小，本次获批上市的 高敏心肌肌钙蛋白 I（hs-cTnI）测定试剂盒（荧光免疫层析法）的投产及对公司 业绩的后续影响具有不确定性，请广大投资者注意投资风险。 2. 本次产品获证后还未投入生产，其实际销售情况受市场拓展力度及市场 实际需求等多重因素影响，目前尚无法预测上述获批产品对公司未来业绩的具体 影响，请广大投资者注意投资风险。 请广大投资者充分阅读本公告正文表述的相关风险事项，公司特别提示投资 者理性投资。 山东东方海洋科技股份有限公司（以下简称"公司"）全资子公司艾维可生物 科技有限公司自主研发的高敏心肌肌钙蛋白 I（hs-cTnI）测定试剂盒（荧光免疫 层析法）于近日取得了山东省药品监督管理局的注册批准，获得医疗器械注册证， 具体情况如下： 一、产品信息 1、高敏心肌肌钙蛋白 I（hs-cTnI）测定试 ...

东方海洋12月24日公告，公司全资子公司艾维可生物科技有限公司自主研发的高敏心肌肌钙蛋白I（hs- cTnI）测定试剂盒（荧光免疫层析法）获得山东省药品监督管理局颁发的医疗器械注册证。 上述产品 获准上市，进一步丰富了艾维可生物科技有限公司在临床检测领域的产品线。但鉴于艾维可生物科技有 限公司今年对公司的业绩影响较小，上述产品的投产以及对公司业绩的后续影响具有不确定性。上述产 品获证后还未投入生产，其实际销售情况受市场拓展力度及市场实际需求等多重因素影响，目前尚无法 预测上述产品对公司未来业绩的具体影响。 ...

Group 1 - The median annualized yield of money market funds has dropped to 1.23%, a nearly 20% decrease since the beginning of the year, with over 130 products falling below the 1% threshold [1] - The latest yield of Tianhong's Yu'ebao is reported at 1.02%, approaching the 1% mark [1] - Public funds have participated in private placements exceeding 35 billion yuan since the beginning of 2025, with over 40% allocated to hard technology sectors, indicating a proactive capital allocation towards emerging industries [1] Group 2 - Insurance capital has invested over 109.7 billion yuan in private equity funds this year, marking a 55.85% increase compared to the same period last year [2] - The Shanghai Stock Exchange has seen a significant increase in refinancing approvals, with nearly 690 billion yuan raised this year and a notable acceleration in review efficiency [2] - There are currently 256 securities eligible for investor claims due to clear violations, with six companies approaching the end of their litigation period [2] Group 3 - The scale of technology innovation bonds has surpassed 1.7 trillion yuan, reflecting a growing ecosystem in the bond market aimed at supporting technological advancements [3] - The People's Bank of China has initiated measures to promote the construction of a "technology board" in the bond market, enhancing financing channels for tech enterprises [3] Group 4 - China National Offshore Oil Corporation announced the discovery of the Qinhuangdao 29-6 oil field, marking the seventh billion-ton oil field found in the Bohai Sea since 2019, which is significant for national energy security [4] - Nvidia plans to deliver H200 AI chips to Chinese customers before the Lunar New Year, with an expected shipment of 5,000 to 10,000 modules, although uncertainties remain regarding the approval of these orders [4] Group 5 - Zhejiang Youbang Integrated Ceiling Co., Ltd. is planning a change in control, leading to a temporary suspension of its stock trading [12] - A subsidiary of Dongfang Yuhong has reported a telecom fraud incident involving approximately 1.7183 million USD, with measures taken to mitigate losses [9] - Xinhua New Materials intends to acquire 70% of Dongwang Technology for 140 million yuan, aiming to enhance its capabilities in AI and digital transformation [11]

Core Viewpoint - Guoyuan Fund, a shareholder holding more than 5% of Dongfang Ocean, has reduced its shareholding in the company, which will not lead to a change in control or significant operational impact [1] Group 1: Shareholding Changes - Guoyuan Fund reduced its holdings on November 17, and from December 19 to 22, selling a total of 15.385 million shares through centralized bidding [1] - On December 23, Guoyuan Fund further reduced its holdings by 480,000 shares through block trading, totaling a reduction of 15.865 million shares, which accounts for 0.81% of the total share capital [1] - Following these transactions, Guoyuan Fund's shareholding decreased to 118 million shares, representing a 6% stake, with the change touching the 1% integer threshold [1] Group 2: Compliance with Plans - The share reduction aligns with the previously announced plan and has not yet been fully executed [1]

证券代码：002086 证券简称：东方海洋 公告编号：2025-069 关于持股 5%以上股东股份变动触及 1%整数倍的公告 国元基金保证向本公司提供的信息内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 深圳前海国元私募证券基金管理有限公司－国元价值精选一号私募证券投 资基金（以下简称"国元基金"）为持有山东东方海洋科技股份有限公司（以下简 称"公司"）5%以上股份的大股东。公司于 2025 年 11 月 11 日披露《关于持股 5% 以上股东减持股份触及 1%整数倍的公告》（公告编号：2025-061），国元基金 通过大宗交易及集中竞价方式合计减持公司股份 19,580,000 股，占公司总股本的 1%，持股比例由 8.00%变更为 7.00%。公司于 2025 年 11 月 18 日披露《关于持 股 5%以上股东减持股份实施情况的公告》（公告编号：2025-062），国元基金 于 11 月 17 日继续减持 3,715,000 股，此次减持实施完毕，其累计减持公司股份 58,740,000 股，持股比例变为 6.81%。公 ...

第1笔成交价格为2.36元，成交48.00万股，成交金额113.28万元，溢价率为0.00%，买方营业部为国盛证 券有限责任公司苏南分公司，卖方营业部为华泰证券股份有限公司绍兴府山证券营业部。 进一步统计，近3个月内该股累计发生1笔大宗交易，合计成交金额为113.28万元。该股近5个交易日累 计下跌0.84%，主力资金合计净流出3061.66万元。 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 12月23日，东方海洋收跌1.67%，收盘价为2.36元，发生1笔大宗交易，合计成交量48万股，成交金额 113.28万元。 责任编辑：小浪快报 ...

| 权益类证券大宗交易 (协议交易) | | --- | 12月23日，东方海洋大宗交易成交48万股，成交额113.28万元，占当日总成交额的1.4%，成交价2.36 元，较市场收盘价2.36元持平。 | 交易日期 | 证券代码 | 证券简称 | 成交价格 | 成交量 | 成交金额 (万元) | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | (元) | (万股/万份) | | | | | 2025-12-23 | 002086 | 东方海洋 | 2.36 | 48.00 | | 113.28 国盛证券有限责任 | 华泰证券股份有限 | | | | | | | | 公司苏南分公司 | 公司绍兴府山证券 | | | | | | | | | 营业部 | ...

Core Viewpoint - Dongfang Ocean's subsidiary, Aiveke Biotechnology Co., Ltd., has received regulatory approval for its procalcitonin (PCT) testing kit, marking a significant advancement in its product offerings [1] Group 1 - The PCT testing kit is developed using a fluorescence immunochromatography method [1] - The kit has been approved by the Shandong Provincial Drug Administration and has received a medical device registration certificate [1] - The registration certificate number is Lu Xie Zhu Zheng 20252400747, with a validity period from December 11, 2025, to December 10, 2030 [1]

Group 1 - Rongchang Biotech plans to repurchase shares worth between 20 million and 40 million yuan, with a maximum price of 95 yuan per share, aiming to buy back approximately 21,050 to 42,110 shares, representing about 0.04% to 0.07% of total share capital [1] - Nanya New Materials intends to raise no more than 900 million yuan through a private placement for AI computing power-based high-frequency high-speed copper-clad laminate R&D and working capital [2] - Xiechuang Data has signed a strategic cooperation agreement with Ping An Financial Leasing, aiming for a cooperation scale of 2 billion yuan over three years [3] Group 2 - Chuangshi Technology's controlling shareholder is under investigation and has been placed under detention, having resigned from all positions in the company [4] - Deep Kangjia A has reported overdue shareholder loans to Yikang Technology and Chuzhou Kangxin, totaling approximately 233 million yuan and 395 million yuan respectively, due to repayment issues [5] - Ningbo Yuanyang announced the resignation of two directors due to work adjustments [6] Group 3 - China Merchants Energy has delivered the world's first methanol dual-fuel VLCC oil tanker, with 15 oil tanker orders in hand [7] - Tianyu Co., Ltd. has received a drug registration certificate for hydrochloride trazodone tablets, which are used for treating depression [8] - Haizheng Pharmaceutical has received FDA approval for clinical trials of HS387 tablets for treating advanced solid tumors [9] Group 4 - Warner Pharmaceuticals has obtained a drug registration certificate for isoproterenol hydrochloride injection, used for treating shock and complete atrioventricular block [10] - Hekang New Energy's subsidiary received a government subsidy of 1.5 million yuan, which accounts for 14.57% of the company's latest audited net profit [11] - Duku Culture is planning a change in company control, with stock suspension expected for no more than two trading days [12] Group 5 - Haisco has received acceptance for an IND application for HSK46575 tablets for prostate cancer treatment [13] - *ST Xinyan is executing a capital reserve transfer to increase share capital, resulting in a stock suspension [14] - Nanjing Public Utilities is transferring a 45% stake in a subsidiary for 23.6443 million yuan [15] Group 6 - Action Education plans to repurchase shares worth between 20 million and 25 million yuan, with a maximum price of 45 yuan per share [16] - Bai'ao Tai has received government subsidies totaling 29 million yuan [18] - Weisi Medical intends to sell assets worth 119 million yuan, expecting a profit impact of approximately 10 million yuan [19] Group 7 - Tongyu Communications plans to increase capital by 10 million yuan to introduce investment from Wuchuang Institute [20] - Dongtu Technology's subsidiary is introducing strategic investor Guofeng Investment Fund with a capital increase of 11 million yuan [21] - China General Nuclear Power Technology's shareholder is facing a judicial auction of 2.91% of the company's shares [22] Group 8 - Nanshan Aluminum plans to repurchase shares worth between 300 million and 600 million yuan, with a maximum price of 7.52 yuan per share [23] - Yipin Hong's controlling shareholder has committed to transferring 9.07% equity in Arthrosi without compensation [24] - Sanli Pharmaceutical has signed a technology transfer contract worth 200 million yuan with Hainan University [25] Group 9 - Xin Nuo Wei plans to jointly invest 450 million yuan with Zhongqi Pharmaceutical to establish a joint venture focusing on innovative metabolic drugs [26] - Li Qun Co. has been approved to issue 1 billion yuan in medium-term notes to optimize debt structure and supplement working capital [27] - Dongfang Ocean's subsidiary has received a medical device registration certificate for a procalcitonin test kit [28] Group 10 - Tibet Mining's chairman has resigned due to work adjustments [29] - Wantai Biological's subsidiary has been shortlisted for a national immunization program vaccine procurement project, with a bid price of 27.5 yuan [30] - Xingfu Blue Sea has appointed Zhang Chen as the new deputy general manager [31] Group 11 - Changyuan Donggu has elected Li Yixuan as the vice chairman of the board [32] - Ningbo Huaxiang's subsidiary has signed a strategic cooperation agreement with Dahuang Robotics for collaboration in humanoid robot development [33] - Yongda Co. has been pre-selected for a procurement project worth approximately 350 million yuan [34] Group 12 - Fuan Pharmaceutical's subsidiary has received a drug registration certificate for hydrochloride trazodone tablets [35] - Nanjing Food reported a 71.03% year-on-year decrease in net profit for November due to rising raw material costs [36] - Changqing Technology's special polymer monomer project has commenced production [37]